Drugs / DC vaccine
DC vaccine
also known as
Dendritic cell vaccine · Autologous DC vaccine · DC Vaccine - Dendritic Cell Vaccine · DC1 vaccine · Human CMV pp65-LAMP mRNA-pulsed autologous DCs · Immunotherapy based on dendritic cells · tumor antigen loaded autologous dendritic cells · autologous dendritic cell cancer vaccine · +8 more
Trials 52 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02548169 Comparator | Aug 2015 → Apr 2017 | malignant pancreatic neoplasm | Baylor Research Institute | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00402142 Comparator | Nov 2006 → Dec 2011 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03384914 Comparator | Feb 2018 → Dec 2025 overdue | HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 56 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC vaccine | “autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine)” NCT00862303 ↗23 |
| Known as | Autologous DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04166006 ↗ |
| Known as | autologous dendritic cell cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103116 ↗ |
| Known as | BIIR/ANRS-HIVax-001 | “vaccination with ex vivo generated interferon-alpha dendritic cells loaded with HIV-1 lipopeptides and activated with lipopolysaccharide (BIIR/ANRS-HIVax-001, the DC vaccine product).” NCT00796770 ↗ |
| Known as | cDC1 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07694986 ↗ |
| Known as | DC Vaccine - Dendritic Cell Vaccine | “DC Vaccine ( Dendritic cell vaccine)” NCT00722098 ↗1“DC Vaccine - Dendritic Cell Vaccine” NCT02018458 ↗ |
| Known as | DC1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00970203 ↗ |
| Known as | DCV | “The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given...” NCT05809752 ↗ |
| Known as | Dendritic cell vaccine | “The purpose of this study is to test the safety and effects of a special type of a cancer vaccine called a 'dendritic cell vaccine' in patients with either newly diagnosed or...” NCT02010606 ↗ |
| Known as | Dendritic Cell Vaccine - DC Vaccine | “Dendritic Cell Vaccine - DC Vaccine” NCT00313235 ↗ |
| Known as | Human CMV pp65-LAMP mRNA-pulsed autologous DCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03688178 ↗ |
| Known as | Immunotherapy based on dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03214939 ↗ |
| Known as | MDDCT | “We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific...” PMID 35022035 ↗ Jan 2022 |
| Known as | Monocyte-Derived Dendritic-cell Therapy | “We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific...” PMID 35022035 ↗ Jan 2022 |
| Known as | Neo-DC vaccine | “This is a clinical study of personalized self-DC vaccine targeting neo-antigen (Neo-DC vaccine) in the treatment of advanced solid tumors.” NCT06682117 ↗ |
| Known as | tumor antigen loaded autologous dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00197860 ↗ |
| Known as | αDC1 | “intradermal (ID) autologous αDC1 vaccines (known to be nontoxic)” NCT02432378 ↗ |
| Action | Deplete | “dendritic cell vaccination can significantly prevent relapse and increase survival of AML patients by eradicating minimal residual disease” NCT01686334 ↗ |
| Modality | Vaccine | “Dendritic cell vaccine plus denileukin difitox” NCT00056134 ↗ |
| Route | Subcutaneous | “Patients receive 4 pulsed DC vaccinations subcutaneously (SC)” NCT00056134 ↗ |
| Target | WT1 | “loaded by messenger RNA electroporation with the Wilms' tumor antigen (WT1)” NCT01686334 ↗ |